AU2021222339B2 - A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent - Google Patents

A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Info

Publication number
AU2021222339B2
AU2021222339B2 AU2021222339A AU2021222339A AU2021222339B2 AU 2021222339 B2 AU2021222339 B2 AU 2021222339B2 AU 2021222339 A AU2021222339 A AU 2021222339A AU 2021222339 A AU2021222339 A AU 2021222339A AU 2021222339 B2 AU2021222339 B2 AU 2021222339B2
Authority
AU
Australia
Prior art keywords
cisplatin
fluorouracil
lomustine
artemisinin
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021222339A
Other languages
English (en)
Other versions
AU2021222339A1 (en
Inventor
Ulrich Elling
Josef Martin Penninger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jlp Health GmbH
Original Assignee
Jlp Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jlp Health GmbH filed Critical Jlp Health GmbH
Publication of AU2021222339A1 publication Critical patent/AU2021222339A1/en
Application granted granted Critical
Publication of AU2021222339B2 publication Critical patent/AU2021222339B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021222339A 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent Active AU2021222339B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158341.6 2020-02-19
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
PCT/EP2021/054039 WO2021165405A1 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Publications (2)

Publication Number Publication Date
AU2021222339A1 AU2021222339A1 (en) 2022-07-28
AU2021222339B2 true AU2021222339B2 (en) 2026-05-21

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021222339A Active AU2021222339B2 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Country Status (15)

Country Link
US (1) US20230121771A1 (cg-RX-API-DMAC7.html)
EP (2) EP3868372A1 (cg-RX-API-DMAC7.html)
JP (1) JP7719787B2 (cg-RX-API-DMAC7.html)
KR (1) KR102988319B1 (cg-RX-API-DMAC7.html)
CN (1) CN114786661A (cg-RX-API-DMAC7.html)
AU (1) AU2021222339B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022014692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165208A1 (cg-RX-API-DMAC7.html)
DK (1) DK3989961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972799T3 (cg-RX-API-DMAC7.html)
FI (1) FI3989961T3 (cg-RX-API-DMAC7.html)
IL (1) IL294856A (cg-RX-API-DMAC7.html)
PL (1) PL3989961T3 (cg-RX-API-DMAC7.html)
PT (1) PT3989961T (cg-RX-API-DMAC7.html)
WO (1) WO2021165405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018082120A1 (zh) * 2016-11-04 2018-05-11 吉林省北方医药有限责任公司 一种移动终端设备
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用
WO2019141988A1 (en) * 2018-01-17 2019-07-25 St George's Hospital Medical School Combination therapy for treatment of leukemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN108570089B (zh) * 2017-04-28 2019-10-29 云白药征武科技(上海)有限公司 双氢青蒿素-甾体结合物及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018082120A1 (zh) * 2016-11-04 2018-05-11 吉林省北方医药有限责任公司 一种移动终端设备
WO2019141988A1 (en) * 2018-01-17 2019-07-25 St George's Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C-P CHEN ET AL: "Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression", ACTA PHARMA SINICA B, 9, 5, 2019, 937-951, DOI: 10.1016/j.apsb.2019.05.001 *
J WANG ET AL: "Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal", ACS CENTRAL SCIENCE, 3, 7, 2017, 743-750, DOI: 10.1021/acscentsci.7b00156 *
T OSAKI ET AL: "Antimalarial Drugs Enhance the Cytotoxicity of 5-Aminolevulinic Acid-Based Photodynamic Therapy against the Mammary Tumor Cells of Mice In Vitro", MOLECULES, vol. 24, no. 21, 2019 pages 3891, DOI: 10.3390/molecules24213891 *
TOMOHIRO OSAKI ET AL: "Artesunate Enhances the Cytotoxicity of 5-Aminolevulinic Acid-Based Sonodynamic Therapy against Mouse Mammary Tumor Cells In Vitro", MOLECULES, vol. 22, no. 4, 2017, pages 533, DOI: 10.3390/molecules22040533 *
YUNQIN ZHANG ET AL: "Antitumor Research on Artemisinin and Its Bioactive Derivatives", NATURAL PRODUCTS AND BIOPROSPECTING, vol. 8, no. 4, 9 April 2018 (2018-04-09), pages 303 - 319, DOI: 10.1007/s13659-018-0162-1 *

Also Published As

Publication number Publication date
PT3989961T (pt) 2024-02-26
WO2021165405A1 (en) 2021-08-26
DK3989961T3 (da) 2024-01-29
JP2023514426A (ja) 2023-04-05
IL294856A (en) 2022-09-01
JP7719787B2 (ja) 2025-08-06
BR112022014692A2 (pt) 2022-09-20
KR102988319B1 (ko) 2026-07-07
CN114786661A (zh) 2022-07-22
EP3868372A1 (en) 2021-08-25
US20230121771A1 (en) 2023-04-20
EP3989961A1 (en) 2022-05-04
FI3989961T3 (fi) 2024-02-14
AU2021222339A1 (en) 2022-07-28
KR20220143097A (ko) 2022-10-24
PL3989961T3 (pl) 2024-04-08
CA3165208A1 (en) 2021-08-26
EP3989961B1 (en) 2023-11-22
ES2972799T3 (es) 2024-06-17

Similar Documents

Publication Publication Date Title
US12023328B2 (en) Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US11639335B2 (en) Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
KR102630889B1 (ko) 키나제를 조절하는 화합물의 고형 형태
US8143247B2 (en) Combinations for the treatment of diseases involving cell proliferation
CA2773838C (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
CN116096704A (zh) 用于治疗癌症的组合疗法
US20210070712A1 (en) Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy
CN101406473A (zh) 二氢嘧啶化合物的用途及含其的药物组合物
AU2012271814A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
JP2017519019A (ja) mdm2阻害剤の間欠投与
CN103687853A (zh) 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途
EP3697767B1 (en) Compounds and methods for treating cancer
CN111655669A (zh) 治疗包括运动神经元疾病的神经紊乱的组合物和方法
EP3989961B1 (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
KR20180037975A (ko) 포도막 흑색종을 치료하기 위한 mdm2 억제제
RU2847295C1 (ru) Фармацевтическая комбинация соединения артемизинина, 5- аминолевулиновой кислоты или метил-5-аминолевулиновой кислоты и химиотерапевтического агента
WO2005089496A2 (en) Methods for the treatment of synucleinopathies
HK40074153A (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
HK40074153B (en) A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent
WO2021046178A1 (en) Compounds and methods for treating cancer
TW201315470A (zh) 吡咯並喹啉基-吡咯啶-2,5-二酮調製劑類及製備和使用彼等之方法
WO2021046220A1 (en) Compounds and methods for treating cancer
HK40113709A (en) Therapeutic combinations comprising ubiquitin specific-processing protease 1 (usp1) inhibitors and chemotherapy agents
EA052090B1 (ru) Композиции 1-(4-бром-5-(1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил)-2-фторфенил)-3-фенилмочевины
HK40031775A (en) Compounds and methods for treating cancer